Harvard Bioscience Inc (HBIO)

$2.53

+0.21

(+9.05%)▲

Market is closed - opens 7 PM, 14 Oct 2024

Performance

  • $2.32
    $2.53
    $2.53
    downward going graph

    8.3%

    Downside

    Day's Volatility :8.3%

    Upside

    0.0%

    downward going graph
  • $2.32
    $5.56
    $2.53
    downward going graph

    8.3%

    Downside

    52 Weeks Volatility :58.27%

    Upside

    54.5%

    downward going graph

Returns

PeriodHarvard Bioscience IncSector (Health Care)Index (Russel 2000)
3 Months
-23.8%
3.8%
0.0%
6 Months
-43.02%
10.8%
0.0%
1 Year
-38.89%
18.2%
0.0%
3 Years
-61.9%
22.6%
-21.1%

Highlights

Market Capitalization
110.3M
Book Value
$1.54
Earnings Per Share (EPS)
-0.27
PEG Ratio
2.89
Wall Street Target Price
6.25
Profit Margin
-10.56%
Operating Margin TTM
-7.24%
Return On Assets TTM
-1.62%
Return On Equity TTM
-14.97%
Revenue TTM
101.1M
Revenue Per Share TTM
2.35
Quarterly Revenue Growth YOY
-19.7%
Gross Profit TTM
62.3M
EBITDA
3.6M
Diluted Eps TTM
-0.27
Quarterly Earnings Growth YOY
-0.8
EPS Estimate Current Year
0.12
EPS Estimate Next Year
0.15
EPS Estimate Current Quarter
0.05
EPS Estimate Next Quarter
0.06

Analyst Recommendation

Buy
    88%Buy
    11%Hold
    0
    0%Sell
Based on 9 Wall street analysts offering stock ratings for Harvard Bioscience Inc(by analysts ranked 0 to 5 stars)
Based on 9 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
8
8
8
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 147.04%

Current $2.53
Target $6.25

Company Financials

FY18Y/Y Change
Revenue
120.8M
↑ 18.54%
Net Income
-3.5M
↑ 300.23%
Net Profit Margin
-2.87%
↓ 2.02%
FY19Y/Y Change
Revenue
116.2M
↓ 3.81%
Net Income
-4.7M
↑ 35.38%
Net Profit Margin
-4.03%
↓ 1.16%
FY20Y/Y Change
Revenue
102.1M
↓ 12.12%
Net Income
-7.8M
↑ 66.63%
Net Profit Margin
-7.65%
↓ 3.62%
FY21Y/Y Change
Revenue
118.9M
↑ 16.46%
Net Income
-288.0K
↓ 96.31%
Net Profit Margin
-0.24%
↑ 7.41%
FY22Y/Y Change
Revenue
113.3M
↓ 4.68%
Net Income
-9.5M
↑ 3204.17%
Net Profit Margin
-8.4%
↓ 8.16%
FY23Y/Y Change
Revenue
112.3M
↓ 0.96%
Net Income
-3.4M
↓ 64.11%
Net Profit Margin
-3.04%
↑ 5.36%
Q1 FY23Q/Q Change
Revenue
30.0M
↑ 5.45%
Net Income
622.0K
↓ 137.33%
Net Profit Margin
2.08%
↑ 7.94%
Q2 FY23Q/Q Change
Revenue
28.8M
↓ 4.06%
Net Income
-980.0K
↓ 257.56%
Net Profit Margin
-3.41%
↓ 5.49%
Q3 FY23Q/Q Change
Revenue
25.4M
↓ 11.81%
Net Income
-1.2M
↑ 26.43%
Net Profit Margin
-4.89%
↓ 1.48%
Q4 FY23Q/Q Change
Revenue
28.2M
↑ 11.0%
Net Income
-1.8M
↑ 46.73%
Net Profit Margin
-6.46%
↓ 1.57%
Q1 FY24Q/Q Change
Revenue
24.5M
↓ 12.93%
Net Income
-4.7M
↑ 158.2%
Net Profit Margin
-19.15%
↓ 12.69%
Q2 FY24Q/Q Change
Revenue
23.1M
↓ 5.77%
Net Income
-2.9M
↓ 37.64%
Net Profit Margin
-12.67%
↑ 6.48%
FY18Y/Y Change
Total Assets
168.1M
↑ 53.7%
Total Liabilities
85.9M
↑ 201.85%
FY19Y/Y Change
Total Assets
164.9M
↓ 1.91%
Total Liabilities
83.2M
↓ 3.16%
FY20Y/Y Change
Total Assets
156.3M
↓ 5.23%
Total Liabilities
79.6M
↓ 4.33%
FY21Y/Y Change
Total Assets
162.3M
↑ 3.9%
Total Liabilities
78.9M
↓ 0.79%
FY22Y/Y Change
Total Assets
145.4M
↓ 10.46%
Total Liabilities
73.1M
↓ 7.35%
FY23Y/Y Change
Total Assets
137.4M
↓ 5.5%
Total Liabilities
64.3M
↓ 12.1%
Q1 FY23Q/Q Change
Total Assets
145.6M
↑ 0.15%
Total Liabilities
71.2M
↓ 2.6%
Q2 FY23Q/Q Change
Total Assets
142.9M
↓ 1.84%
Total Liabilities
67.5M
↓ 5.23%
Q3 FY23Q/Q Change
Total Assets
139.7M
↓ 2.21%
Total Liabilities
65.4M
↓ 3.05%
Q4 FY23Q/Q Change
Total Assets
137.4M
↓ 1.7%
Total Liabilities
64.3M
↓ 1.77%
Q1 FY24Q/Q Change
Total Assets
133.2M
↓ 3.06%
Total Liabilities
64.3M
↑ 0.09%
Q2 FY24Q/Q Change
Total Assets
128.9M
↓ 3.19%
Total Liabilities
61.7M
↓ 4.17%
FY18Y/Y Change
Operating Cash Flow
2.3M
↑ 121.76%
Investing Cash Flow
-53.8M
↑ 5766.52%
Financing Cash Flow
53.1M
↓ 3060.55%
FY19Y/Y Change
Operating Cash Flow
8.0M
↑ 243.3%
Investing Cash Flow
-229.0K
↓ 99.57%
Financing Cash Flow
-7.6M
↓ 114.37%
FY20Y/Y Change
Operating Cash Flow
9.3M
↑ 15.96%
Investing Cash Flow
-1.4M
↑ 512.23%
Financing Cash Flow
-8.0M
↑ 4.47%
FY21Y/Y Change
Operating Cash Flow
1.3M
↓ 86.48%
Investing Cash Flow
-1.3M
↓ 4.07%
Financing Cash Flow
-252.0K
↓ 96.84%
FY22Y/Y Change
Operating Cash Flow
1.2M
↓ 8.72%
Investing Cash Flow
-1.6M
↑ 18.22%
Financing Cash Flow
-2.8M
↑ 1025.79%
Q1 FY23Q/Q Change
Operating Cash Flow
1.8M
↓ 32.36%
Investing Cash Flow
288.0K
↓ 222.55%
Financing Cash Flow
-2.9M
↑ 5.97%
Q2 FY23Q/Q Change
Operating Cash Flow
3.6M
↑ 96.03%
Investing Cash Flow
-625.0K
↓ 317.01%
Financing Cash Flow
-2.4M
↓ 17.91%

Technicals Summary

Sell

Neutral

Buy

Harvard Bioscience Inc is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Harvard Bioscience Inc
Harvard Bioscience Inc
-12.15%
-43.02%
-38.89%
-61.9%
-6.3%
Intuitive Surgical, Inc.
Intuitive Surgical, Inc.
-1.04%
28.47%
77.48%
48.71%
180.28%
Resmed Inc.
Resmed Inc.
-3.38%
29.94%
71.49%
-4.65%
86.12%
Becton, Dickinson And Company
Becton, Dickinson And Company
0.99%
0.76%
-8.58%
-1.39%
-5.67%
West Pharmaceutical Services Inc
West Pharmaceutical Services Inc
-1.92%
-22.15%
-23.41%
-26.68%
108.2%
Alcon Ag
Alcon Ag
-1.84%
19.24%
28.58%
23.06%
69.54%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Harvard Bioscience Inc
Harvard Bioscience Inc
NA
NA
2.89
0.12
-0.15
-0.02
NA
1.54
Intuitive Surgical, Inc.
Intuitive Surgical, Inc.
83.3
83.3
4.18
6.65
0.16
0.08
NA
41.4
Resmed Inc.
Resmed Inc.
34.71
34.71
2.0
7.71
0.23
0.13
0.01
33.11
Becton, Dickinson And Company
Becton, Dickinson And Company
47.39
47.39
1.09
13.11
0.06
0.03
0.02
89.5
West Pharmaceutical Services Inc
West Pharmaceutical Services Inc
42.01
42.01
5.03
6.51
0.2
0.11
0.0
35.49
Alcon Ag
Alcon Ag
43.55
43.55
3.63
3.06
0.05
0.03
0.0
42.35
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Harvard Bioscience Inc
Harvard Bioscience Inc
Buy
$110.3M
-6.3%
NA
-10.56%
Intuitive Surgical, Inc.
Intuitive Surgical, Inc.
Buy
$172.3B
180.28%
83.3
27.65%
Resmed Inc.
Resmed Inc.
Buy
$35.3B
86.12%
34.71
21.79%
Becton, Dickinson And Company
Becton, Dickinson And Company
Buy
$68.4B
-5.67%
47.39
7.13%
West Pharmaceutical Services Inc
West Pharmaceutical Services Inc
Buy
$21.4B
108.2%
42.01
18.25%
Alcon Ag
Alcon Ag
Buy
$47.7B
69.54%
43.55
11.44%

Insights on Harvard Bioscience Inc

  • Decreasing Revenue

    Revenue is down for the last 3 quarters, 28.15M → 23.09M (in $), with an average decrease of 9.4% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -4.69M → -2.92M (in $), with an average increase of 60.4% per quarter

  • Vs ISRG

    In the last 1 year, Intuitive Surgical, Inc. has given 77.5% return, outperforming this stock by 116.4%

  • Vs ISRG

    In the last 3 years, Intuitive Surgical, Inc. has given 48.7% return, outperforming this stock by 110.6%

Institutional Holdings

  • BlackRock Inc

    6.52%

  • Punch & Associates Inv Mgmt Inc

    6.36%

  • Harvey Partners LLC

    5.86%

  • AMH Equity Ltd

    5.04%

  • Vanguard Group Inc

    4.86%

  • Granahan Investment Management Inc..

    4.41%

Company Information

harvard bioscience is a global developer, manufacturer and marketer of a broad range of specialized products, primarily apparatus and scientific instruments used to advance life science research at pharmaceutical and biotechnology companies, universities and government laboratories worldwide. we sell our products to thousands of researchers in over 100 countries through our full-line catalog (and various other specialty catalogs), our websites, and through distributors, including ge healthcare, thermo fisher scientific inc., and vwr. we have sales and manufacturing operations in the united states, the united kingdom, germany, and spain and sales facilities in france and canada.

Organization
Harvard Bioscience Inc
Employees
391
CEO
Mr. James W. Green
Industry
Health Technology

Discover More

FAQs